Beyond cyp2c19 - a new chapter in clopidogrel pharmacogenomics

Thomas M. Polasek

    Research output: Contribution to journalEditorial

    1 Citation (Scopus)


    Combination antiplatelet therapy with clopidogrel and aspirin is routine following coronary artery stenting. Worldwide, more than 2 million people undergo this procedure each year, making clopidogrel the second most prescribed drug in the world (over US$9 billion in sales in 2010).1 There is considerable inter-individual variability in platelet response to clopidogrel, which means that patients with a low response are at a significant risk of thromboembolic complications, such as fatal stent thrombosis.2 Therefore, identifying factors that influence clopidogrel efficacy is crucial.

    Original languageEnglish
    Pages (from-to)14-16
    Number of pages3
    JournalJournal of Pharmacy Practice and Research
    Issue number1
    Publication statusPublished - Mar 2011

    Bibliographical note

    Copyright 2017 Elsevier B.V., All rights reserved.


    Dive into the research topics of 'Beyond cyp2c19 - a new chapter in clopidogrel pharmacogenomics'. Together they form a unique fingerprint.

    Cite this